Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0754 · 1 trial · 1 indication
Determine if treatment with AZD0754 is safe and tolerable through assessment of DLTs/DLT-like events, AEs, AESIs, SAEs, and changes from baseline in laboratory parameters, vital signs, and ECGs.
| Arm | Type | Description |
|---|---|---|
| AZD0754 | EXPERIMENTAL | AZD0754 monotherapy for treatment of participants with metastatic prostate cancer. |
| AZD2287 | EXPERIMENTAL | AZD2287 is a novel imaging agent for STEAP2 |
| Name | Type | Description |
|---|---|---|
| AZD0754 | BIOLOGICAL | Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754. During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy. Study treatment will include lymphodepleting chemotherapy. After lymphodepleting chemotherapy AZD0754 is administered intravenously and patients will be required to stay at the hospital for a protocol specified monitoring period. |
| AZD2287 | BIOLOGICAL | This is an Optional arm of the study, which subjects will separately consent to if they would like to participate. Subjects will receive doses of a radioactive imaging agent called AZD2287 followed by SPECT/CT imaging scans at two time points. |
Inclusion Criteria: Age 1. Participant must be 18 years or older at the time of signing the informed consent form. Type of Participant and Disease Characteristics 2. Participants with: 1. A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate without known neuroe...
Top 20 of 53 competitors
AZD0754 is an investigational monoclonal antibody being developed for the treatment of metastatic prostate cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD0754 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials for metastatic prostate cancer.
AZD0754 is in Phase 1 clinical development. It is an investigational drug being studied in a Phase 1 trial for metastatic prostate cancer, and it has not yet been approved for commercial use.
AZD0754 is being studied in a Phase 1 clinical trial with the identifier NCT06267729. This trial is recruiting participants with metastatic prostate cancer and is being conducted in the United States, Australia, and Spain.
Yes, AZD0754 is a monoclonal antibody. It is being investigated as a potential treatment for metastatic prostate cancer and is currently in Phase 1 clinical development.